17, 18, 20,

IN THE CLAIMS:

In order to address the final remaining Examiner rejection and to expedite prosecution, please amend the claims as follows, without prejudice to future prosecution, without disclaimer of any subject matter, and without acknowledgement or presumption that the amendments are in any way related to patentability. Further, no new matter is introduced by the instant amendments.

1 – 16. (Canceled)

comp

17. (Previously Presented) A product containing an alkylating anthracycline of formula Ia or Ib:



Ia



Ib

An antineopla-

A synergistic antineoplastic composition containing

and an antimetabolite compound, as ~~a combined preparation that~~ has a synergistic antineoplastic effect ~~for use in treatment of tumors in mammals.~~

composition

18. (Previously Presented) The ~~product~~ according to claim 17, further containing a pharmaceutically acceptable carrier or excipient.

composition

Should be Canceled

19. (Previously Presented) The product according to claim 17 or claim 18, wherein the mammal is a human. ?

willing to cancel 19 & 26 if that are the only problem

20. (Previously Presented) The product according to claim 17 or claim 18 wherein the alkylating anthracycline is a 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methanesulfonyl daunorubicin.

21. (Previously Presented) A product according to claim 17 or claim 18 wherein the antimetabolite compound is a cytidine analog.

22. (Previously Presented) A product according to claim 17 or claim 18 wherein the antimetabolite compound is a 5-fluoropyrimidine.

23. (Previously Presented) A product according to claim 21 wherein the cytidine analog is gemcitabine.

24. (Previously Presented) A product according to claim 22 wherein the 5-fluoropyrimidine is 5-fluorouracil.

25. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as an active ingredient, an alkylating anthracycline of formula Ia or Ib as defined in claim 17 and an antimetabolite compound that has a synergistic antineoplastic effect in mammals.

26. (Previously Presented) A pharmaceutical composition according to claim 25 wherein the mammal is a human.

27 (Previously Presented) A pharmaceutical composition according to claim 25 or claim 26 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.

28. (Previously Presented) A method for treating tumors in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

29. (Previously Presented) The method according to claim 28 wherein the mammal is a human.

30. (Currently Amended) The method according to claim 28 or claim 29 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

31. (Canc led)

32. (Previously Presented) A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

33. (Previously Presented) The method according to claim 32 wherein the mammal is a human.

34. (Currently Amended) The method according to claim 32 or claim 33 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

35. (Canceled)

36. (Previously Presented) A method for treating a tumor by the inhibition of angiogenesis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

37. (Previously Presented) The method according to claim 36 wherein the mammal is a human.

38. (Currently Amended) The method according to claim 36 or claim 37 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

39. (Canceled)